New hope for tough colorectal cancers? early trial combines three drugs
NCT ID NCT07656038
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-phase trial tests a new drug called nelmastobart, combined with two existing cancer drugs (TAS-102 and bevacizumab), in 45 Chinese patients with advanced colorectal cancer that has not responded to standard treatments. The main goal is to check safety and how the body handles the drugs, with a preliminary look at whether tumors shrink. It is a small, first-in-human study in China, so results are very preliminary.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- nelmastobart (a monoclonal antibody) combined with TAS-102 (chemotherapy) and bevacizumab (anti-angiogenic drug)
- What this could lead to
- If successful, this could point toward a new treatment option for patients with advanced colorectal cancer who have run out of standard therapies.
- What could go wrong
- This is a very early Phase 1 trial with only 45 participants, so it is primarily testing safety, not effectiveness. The combination may cause significant side effects or fail to shrink tumors.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COLONRECTAL CANCER (CRC) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.